Other news

u-card-img-1
News
Important collaboration agreement with Kaneka Eurogentec

From fundamental research on bacterial stress to the production of biomedicines.

The use of biomedicines is disrupting current medicine

Kaneka and its Walloon subsidiary, Kaneka Eurogentec S.A., enter into a partnership with Pr Jean-François Collet's laboratory (WELBIO UCLouvain) by funding a new joint research group at the Duve Institute.

Learn more
u-card-img-1
News
Déclarez-vous volontaire !

Luttons tous ensemble contre le Covid-19

Boostons la recherche clinique

WELBIO lance aujourd’hui une plateforme digitale permettant aux citoyens de se déclarer volontaires pour des études cliniques relatives au Covid-19 : https://rechercheclinique.be/

Learn more
u-card-img-1
News
Publication in Science Translational Medicine

A new target and a potential cure of cardiac hypertrophy inspired from plant biology

Blockade of transmembrane transport of hydrogen peroxide by cardiac Aquaporin-1 with Brahmi prevents myocardial remodelling

These results from the team of Jean-Luc Balligand (WELBIO – IREC - UCLouvain) pave the way for the development of more potent molecules to block aquaporin and treat heart failure more efficiently.

Learn more
u-card-img-1
News
Publication in Gut

Targeting our second brain to fight diabetes

A ‘jammer’ blocks communication between the gut and the brain

This jammer prevents proper regulation of sugar, causing insulin resistance in people with diabetes. Patrice Cani (UCLouvain) and Claude Knauf (INSERM) also discover that a lipid produced by our body helps preventing this dysfunction.

Learn more
u-card-img-1
News
Publication in Nature Communications

The RNA alphabet is written letter after letter

A new step towards understanding the complex RNA alphabet

François Fuks (WELBIO – ULB) and his colleagues show the key role of a chemically modified RNA letter, hydroxymethylcytosine (hmC), during the differentiation of embryonic stem cells.

Learn more
u-card-img-1
News
Publication in Nature Communications

A novel immunotherapy to fight cancer

Combining two complementary immunotherapies increases the efficacy of treatments against cancer

Sophie Lucas (WELBIO – UCLouvain) and her team neutralize a molecule that blocks immune responses against cancer. This novel form of immunotherapy induces tumor regressions by strongly increasing the efficacy of another well-known immunotherapy.

Learn more
u-card-img-1
News
Publication in Science Translational Medicine

Discovery of a novel gene involved in primary lymphedema

Identifying the genetic causes is crucial for a better management of the disease

The Human Molecular Genetics laboratory headed by Miikka Vikkula (WELBIO – UCLouvain) identified a gene responsible for primary lymphedema, a discovery essential for proper diagnosis and opening possibilities for the development of treatments.

Learn more
u-card-img-1
News
Publication in Nature

Cell-cell communication in stem cell fate choice identified

the molecular mechanisms that control multipotency in different tissues, which have important implications for cancer formation

Researchers led by Cédric Blanpain (WELBIO – ULB) identify for the first time the mechanisms by which cell-cell communication control the fate of mammary and prostate stem cells.

Learn more
u-card-img-1
News
Publication dans Nature

Expansion de la peau: mécanisme dévoilé

Mécanismes moléculaires de génération de la peau

Cédric Blanpain (WELBIO - ULB) et son équipe identifient pour la première fois la manière dont l’étirement active les cellules souches de la peau pour induire l’expansion tissulaire.

Learn more
u-card-img-1
News

Annual report 2019

Information on our projects portfolio, WELBIO investigators, their publications and the awards they received as well as technology transfer progresses.

Learn more
u-card-img-1
News
Publication in eLife

Ammonium’s journey across cell membranes

Ammonia and the proton are transported separately

Anna Maria Marini et Mélanie Boeckstaens (ULB) with teams from Strathclyde and Dundee show that the AmtB protein from the bacteria E. coli separately translocates ammonia and the proton, the ion being carried out by two chains of water molecules.

Learn more
u-card-img-1
News
Publication in Nature Chemical Biology

Click! Resistant bacteria caught in the act

Antibiotic resistance

A team led by Jean-François Collet (WELBIO investigator at UCLouvain), offers an unprecedented perspective on the defense mechanisms of bacteria, contributing to the global effort to respond to antibiotic resistance.

Learn more

Share this page